trial

Sodium Oxybate in Schizophrenia With Insomnia

NCTId NCT00594256
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 8 (actual)
Sponsored by Nathan Kline Institute for Psychiatric Research
Primary completion 2009-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
8 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2008-05
Primary completion
2009-04
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Sodium Oxybate

Sponsors

Nathan Kline Institute for Psychiatric ResearchLead Sponsor
Jazz PharmaceuticalsCollaborator

Investigators

1
Daniel C. Javitt, MD, PhDPrincipal Investigator

Sites

1 total
Orangeburg, United States

Linked catalysts

1
Sodium Oxybate in Schizophrenia With Insomnia — primary completion2009-04

Facts & assertions

4 sourced
Enrollment
8
Phase
PHASE2
Primary Completion Date
2009-04
Status
COMPLETED
relationships
The graph out of here
drug
Sodium Oxybate
drug
lead_sponsor
Nathan Kline Institute for Psychiatric Research
company
collaborator
Jazz Pharmaceuticals
company
indication
Schizophrenia
indication
Sleep Initiation and Maintenance Disorders
indication
Insomnia Related to Schizophrenia (307.42)
indication
investigator
Daniel C. Javitt, MD, PhD
person